BUSINESS
Global Sales of Shionogi’s Novel Influenza Drug Could Reach US$1 Billion: President
Shionogi President Isao Teshirogi suggested on October 30 that sales of the influenza treatment S-033188, which has been granted sakigake fast-track designation, will be affected by the results of an ongoing PIII clinical trial in individuals at high risk for…
To read the full story
Related Article
- Shionogi Notches Double-Digit Sales Rise on HIV/Flu Royalties
October 31, 2017
BUSINESS
- Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role
April 16, 2026
- Suntory to Acquire Daiichi Sankyo’s OTC Business for 246.5 Billion Yen
April 16, 2026
- MSD Debuts HIV Drug Idvynso in Japan in World-First Launch
April 16, 2026
- GSK’s Long-Acting Asthma Drug Exdensur Now Available in Japan
April 16, 2026
- Asahi Kasei Confident of Hitting 2027 Profit Goal, Tarpeyo as Pharma Growth Driver
April 16, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





